» Articles » PMID: 32233054

Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI

Overview
Date 2020 Apr 2
PMID 32233054
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In unresectable hepatocellular carcinoma (HCC), methods to predict patients at increased risk of progression are required.

Purpose: To investigate the feasibility of radiomics model in predicting early progression of unresectable HCC after transcatheter arterial chemoembolization (TACE) therapy using preoperative multiparametric magnetic resonance imaging (MP-MRI).

Study Type: Retrospective.

Population: A total of 84 patients with BCLC B stage HCC from one medical center. According to the modified response evaluation criteria in solid tumors, patients who progressed at 6 months after TACE therapy were assigned as the progressive disease (PD) group (n = 32). Patients whose MRI was performed on four devices were divided into a training cohort (n = 67). Patients whose MRI was performed on other than the previous four devices were used as the testing set (n = 17).

Field Strength/sequence: 3.0T, 1.5T axial T -weighted imaging (T WI), diffusion-weighted imaging (DWI, b = 0, 500 s/mm ), and apparent diffusion coefficient (ADC) ASSESSMENT: PD was confirmed via imaging studies with MRI. Risk factors, including age, alpha fetoprotein (AFP), size, and radiomic-related features of PD were assessed. In addition, the discrimination ability of each radiomics signature was tested on an independent testing set.

Statistical Tests: The area under the receiver-operator characteristic (ROC) curve (AUC) was used to evaluate the predictive accuracy of the radiomic signature in both the training and testing sets. The results indicated that the MP-MRI model achieved the greatest benefit.

Results: In the testing set, the model based on DWI features presented an AUC of (b = 0, 0.786; b = 500, 0.729), followed by T WI features (0.729) and ADC (0.714). The AUC of the MP-MRI signature was increased to 0.800 compared to any single MRI signature. The multivariate logistic analysis identified the radiomics signature as independent parameters of PD, while clinical information such as age, AFP, size, etc., had no significance in the PD group.

Data Conclusion: Preoperative MP-MRI has the potential to predict the outcome of TACE therapy for unresectable HCC. In addition, these image features may be complementary to the current staging systems of HCC patients.

Level Of Evidence: 2.

Technical Efficacy Stage: 3. J. Magn. Reson. Imaging 2020;52:1083-1090.

Citing Articles

Research progress of MRI-based radiomics in hepatocellular carcinoma.

Xie X, Chen R Front Oncol. 2025; 15:1420599.

PMID: 39980543 PMC: 11839447. DOI: 10.3389/fonc.2025.1420599.


TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma.

Wang W, Zhang Q, Cui Y, Zhang S, Li B, Xia T J Hepatocell Carcinoma. 2025; 12:193-203.

PMID: 39896274 PMC: 11787783. DOI: 10.2147/JHC.S490226.


Artificial Intelligence and Machine Learning Predicting Transarterial Chemoembolization Outcomes: A Systematic Review.

Cho E, Law M, Yu Z, Yong J, Tan C, Tan E Dig Dis Sci. 2024; 70(2):533-542.

PMID: 39708260 DOI: 10.1007/s10620-024-08747-5.


Tumor Growth Pattern and Intra- and Peritumoral Radiomics Combined for Prediction of Initial TACE Outcome in Patients with Primary Hepatocellular Carcinoma.

Li J, Zhou M, Tong Y, Chen H, Su R, Tao Y J Hepatocell Carcinoma. 2024; 11:1927-1944.

PMID: 39398867 PMC: 11471153. DOI: 10.2147/JHC.S480554.


Current research status of transarterial therapies for hepatocellular carcinoma.

Zhou M, Zhang P, Mao Q, Wei X, Yang L, Zhang X World J Gastrointest Oncol. 2024; 16(9):3752-3760.

PMID: 39350995 PMC: 11438772. DOI: 10.4251/wjgo.v16.i9.3752.